TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15531007
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg/d
Study: 15531007
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg/d
Study: 9645896
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (1.5 mg/kg body weight, maximum 150 mg)
Study: 9645896
Drug: Intravenous sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sotalol (1.5 mg/kg body weight, maximum 150 mg)
Study: 7840710
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy including indomethacin, essential and dimephosphone
Study: 7840710
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of pathogenetic and antibacterial drugs (monomycin, kanamycin, polymyxin, gentamicin)
Study: 2906248
Drug: N‐696 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐696 (30 mg/d for 7 days)
Study: 2906248
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg/d for 7 days)
Study: 24021498
Drug: Methylphenidate 20
Normalized name: METHYLPHENIDATE 20MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 20 mg daily
Study: 30232597
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg for 14 days
Study: 29201297
Drug: Polmacoxib 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polmacoxib 2 mg
Study: 23819122
Drug: Mydriasert insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mydriasert insert (0.28 mg of tropicamide and 5.4 mg of phenylephrine hydrochloride)
Study: 19922034
Drug: Non-exercising delayed-treatment
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exercising delayed-treatment control group (DTC)
Study: 16773694
Drug: N-acetylcysteine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (two 600 mg doses orally 24 and 12 hours before ERCP and 600 mg IV, twice a day for two days after ERCP)
Study: 16773694
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (IV, twice a day for two days after ERCP)
Study: 15519704
Drug: Viatim vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viatim vaccine
Study: 15519704
Drug: Hepatyrix vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatyrix vaccine
Study: 11760147
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (8 mg PO every 8 hours)
Study: 11760147
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron (1 mg PO every 12 hours)
Study: 11760147
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron (32 mg IV every 24 hours)
Study: 9919425
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued regular treatment)
Study: 8115153
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin treatment
Study: 24104372
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine treatment (1g/m2 d 1, 8, 15, q 4 weeks for 6 months)
Study: 20628405
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg silybin (Legalon Forte) with a vegetarian meal containing 13.9 mg iron
Study: 20628405
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml water
Study: 20628405
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml tea
Study: 18172039
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus pravastatin 10 to 20 mg/d
Study: 18172039
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus pravastatin 10 to 20 mg/d (women ≥ 60 years)
Study: 16948756
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (amiodarone 5 mg/kg and MgSO(4) 1.5 g)
Study: 16948756
Drug: Amiodarone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone group (amiodarone 5 mg/kg)
Study: 14558738
Drug: Cefaclor 375
Normalized name: cefaclor 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 375 mg twice daily
Study: 2140547
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice daily
Study: 7913970
Drug: Levamisole treatment
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole treatment for 1 to 4 months
Study: 7913970
Drug: Levamisole treatment
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole treatment for 4 months
Study: 7913970
Drug: Levamisole treatment
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole treatment for 1-22 months
Study: 7913970
Drug: Levamisole treatment
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole treatment for 3-13 months
Study: 3061974
Drug: Glucagon (0.25-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.25-2 mg, administered intravenously or intramuscularly)
Study: 25063274
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon
Study: 29949232
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin (2 capsules, 5 mg each) once a day for 12 weeks
Study: 24005956
Drug: Simeprevir 50
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 50 mg QD with PegIFNα‐2a/RBV for 24 weeks
Study: 24005956
Drug: Simeprevir 100
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 100 mg QD with PegIFNα‐2a/RBV for 24 weeks
Study: 21761708
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of correction of deviated nasal septum and plasma radiofrequency ablation
Study: 21761708
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of deviated nasal septum and partial inferior turbinectomy
Study: 19476470
Drug: Repaglinide/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide/metformin FDC tablet BID
Study: 19476470
Drug: Rosiglitazone/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone/metformin FDC tablet BID
Study: 15179410
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg subcutaneously, administered twice daily on days 1 to 7)
Study: 7657854
Drug: 80-mg orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-mg orlistat three times a day for 4 1/3 days
Study: 8458364
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg)
Study: 797075
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Study: 797075
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Study: 28745783
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous catheter fixation
Study: 28745783
Drug: Modified intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intravenous catheter fixation
Study: 25560571
Drug: Vildagliptin plus
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin plus metformin
Study: 23958390
Drug: Up-titration of
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-titration of metformin monotherapy
Study: 19172219
Drug: Menatetrenone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (45 mg daily for 6 months)
Study: 19172219
Drug: Calcium aspartate
Normalized name: calcium aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium aspartate (133.8 mg of elemental calcium daily)
Study: 17234537
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of lycopene (Group A, n = 21)
Study: 17234537
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of lycopene along with biweekly intralesional steroid injections (Group B, n = 19)
Study: 8959872
Drug: CsA monotherapy
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA monotherapy
Study: 11562416
Drug: CsA +
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA + steroids (dual therapy)
Study: 11562416
Drug: CsA +
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA + steroids + azathioprine (triple therapy)
Study: 11562416
Drug: CsA monotherapy
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA monotherapy with steroids added
Study: 9565278
Drug: Dentine bonding
Normalized name: dendropanax dentiger root with stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentine bonding agent (DBA)
Study: 1792323
Drug: Boost dose
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boost dose in breast conserving therapy
Study: 1792323
Drug: Treatment planning
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment planning techniques
Study: 1792323
Drug: Dose specification
Normalized name: SPECIFIC GRAVITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose specification
Study: 1792323
Drug: Dose recalculation
Normalized name: CAP,UNIVERSAL,TRACH DECANNULATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose recalculation
Study: 27988390
Drug: Mechanical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical therapy with adjunctive metronidazole
Study: 27988390
Drug: Mechanical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical therapy without adjunctive metronidazole
Study: 26013203
Drug: Aripiprazole augmentation
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole augmentation (AA)
Study: 26013203
Drug: Antidepressant switching
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant switching (SW)
Study: 26013203
Drug: Aripiprazole augmentation
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole augmentation (AA) and Antidepressant switching (SW)
Study: 24725616
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro low mixture (LM25) twice daily
Study: 24725616
Drug: Basal-prandial regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-prandial regimen of insulin glargine once daily and insulin lispro once daily (IGL)
Study: 15761427
Drug: 1064-nm neodymium:yttrium-aluminum-garnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at minimum purpura dose (MPD)
Study: 10467790
Drug: Reformulated 2-rod
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated 2-rod Norplant implant
Study: 8922875
Drug: Original 2-rod
Normalized name: hexylresorcinol 2.4 MG [Sucrets Original]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original 2-rod Norplant implant
Study: 1417482
Drug: Supranormal values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supranormal values of cardiac index (> or = 4.52 L/min per square meter), oxygen delivery (> or = 670 mL/min per square meter), and oxygen consumption (> or = 166 mL/min per square meter)
Study: 4084899
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean daily dose 3.78 mg)
Study: 4084899
Drug: Desipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (mean daily dose 208 mg)
Study: 17484740
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention guided by the Levine Conservation Model; details on dosage and duration not specified.
Study: 15192321
Drug: Asymmetric dimethylarginine
Normalized name: dimethylamine
DrugBank: N,N-dimethylarginine (DB01686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric dimethylarginine (ADMA) infusion
Study: 11336588
Drug: Saquinavir (Fortovase)
Normalized name: saquinavir Oral Capsule [Fortovase]
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saquinavir (Fortovase) co-administered with nucleoside reverse transcriptase inhibitors (nRTIs)
Study: 11336588
Drug: Saquinavir (Fortovase)
Normalized name: saquinavir Oral Capsule [Fortovase]
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saquinavir (Fortovase) co-administered with ritonavir
Study: 11336588
Drug: Saquinavir (Fortovase)
Normalized name: saquinavir Oral Capsule [Fortovase]
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saquinavir (Fortovase) co-administered with nelfinavir
Study: 8365284
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aerosolized pentamidine once monthly
Study: 8365284
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aerosolized pentamidine twice monthly
Study: 8365284
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (300 mg) prophylaxis
Study: 3534025
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin)
Study: 3534025
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of topical sunscreen preparations
Study: 3534025
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of oral contraceptives and other agents that promote skin pigmentation
Study: 27488098
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (fresh oranges and orange juice)
Study: 25322597
Drug: Endoscopic sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sinus surgery (ESS) based comprehensive treatment
Study: 23106412
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) twice a week
Study: 23106412
Drug: Concurrent chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) once a week
Study: 21968659
Drug: 2.5% THPE-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% THPE-containing cream
Study: 16566965
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lignocaine gel with 0.05% chlorhexidine gluconate (group 1, n = 72)
Study: 16566965
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lignocaine and aqueous gel mixture (group 2, n = 69)
Study: 10623705
Drug: Adjuvant active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine, three weekly intradermal vaccine injections of 10^7 irradiated autologous tumor cells and 10^7 BCG organisms for the first two injections
Study: 10623705
Drug: Adjuvant active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine
Study: 1326404
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg sumatriptan sc
Study: 3493795
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at varying rates (60 to 200 micrograms kg‐1 min‐1)
Study: 23988639
Drug: Telmisartan treatment
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan treatment among patients with low eGFR
Study: 19076931
Drug: anti-IgE treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-IgE treatment
Study: 16752286
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate cement augmentation
Study: 14997032
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose p38 MAPK inhibitor (BIRB 796 BS) 600 mg
Study: 14997032
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose p38 MAPK inhibitor (BIRB 796 BS) 50 mg
Study: 9412209
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g once daily parenterally
Study: 9412209
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g 8 hourly for a minimum of 7 days
Study: 8314099
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (individual and family counseling, support group participation, and ad hoc consultation)
Study: 30130147
Drug: L-Dex measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dex measurement using the L-Dex U400 device
Study: 30130147
Drug: Normative values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normative values for L-Dex
Study: 21863338
Drug: Placebo gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gels
Study: 21863338
Drug: All gels
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All gels (including VivaGel(®) and placebo)
Study: 20199360
Drug: 24-hour 10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour 10-mg controlled-release vaginal dinoprostone pessary
Study: 20199360
Drug: Repeat doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of 2 mg vaginal dinoprostone gel
Study: 15660542
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group - catheters flushed with 3 mL of normal saline 0.9% after each catheter use
Study: 15660542
Drug: Heparin group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin group - catheters flushed with 3 mL of 100-U/mL heparin in normal saline 0.9% after each catheter use
Study: 15660542
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - catheters not flushed following drug administration
Study: 10483544
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing 0.5 mg of dinoprostone placed intracervically every four hours
Study: 10483544
Drug: Polymer insert
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer insert containing 10 mg of dinoprostone intravaginally
Study: 6349926
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin supplementation
Study: 24500308
Drug: Paricalcitol-centred therapy
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol-centred therapy (IV and oral)
Study: 24500308
Drug: Paricalcitol-centred therapy
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol-centred therapy
Study: 24500308
Drug: Cinacalcet-centred therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet-centred therapy
Study: 19669013
Drug: 1.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg‐1 of 0.375% bupivacaine associated with 150 (1/4)g of clonidine (2 mL)
Study: 19669013
Drug: 1.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg‐1 of 0.375% bupivacaine associated with NS (2 mL)
Study: 11288210
Drug: Nebulized epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized epinephrine (0.5 mg of 0.1% solution)
Study: 11288210
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (2.5 mg)
Study: 8196140
Drug: rhIL-1ra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-1ra (100 mg loading dose followed by 1.0 or 2.0 mg/kg per hour continuous infusion)
Study: 30795802
Drug: intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal ranibizumab therapy
Study: 11013194
Drug: Hydroxyapatite implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite implant
Study: 11013194
Drug: Acrylic implant
Normalized name: acrylate
DrugBank: Acrylic Acid (DB02579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrylic implant
Study: 12026534
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy (hemodialysis and kidney transplantation)